News Roche pays $1.7 billion for cancer specialist Ignyta Roche is to bolster its cancer pipeline with the $1.7 billion acquisition of Ignyta.
News After surging on lung cancer data, Ignyta looks to raise $16... San Diego based biotech firm Ignyta is capping off a week of success with a public stock offering t
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
